Mezzion Announces Submission of New Drug Application for its Orphan Drug Udenafil to Treat Patients who have undergone the Fontan Operation for Single Ventricle Heart Disease

SEOUL, South Korea, June 30, 2020 /PRNewswire/ -- Mezzion Pharma Co. Ltd. (140410.KQ), announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news